Navigation Links
Breast tomosynthesis after screening mammography reduces need for ultrasound, biopsies
Date:5/7/2014

Leesburg, VA, May 5, 2014Breast tomosynthesis in the diagnostic workup for one- or two-view focal asymmetry detected at screening mammography resulted in less use of ultrasound, fewer biopsies, and higher positive predictive value for cancer than when diagnostic exams involved only 2D mammography, according to a study conducted at the University of Virginia.

"Tomosynthesis has been evaluated in screening populations and been shown to decrease recall rates," said researcher Brandi Nicholson, "but studies in the diagnostic setting are lacking."

Five hundred thirty two patients who were recalled for a focal asymmetric density discovered at screening were analyzed across three categories: women recalled prior to the availability of tomosynthesis in the practice (PT), those who did not have tomosynthesis at diagnostic evaluation after it was available (NT), and those who had diagnostic tomosynthesis (YT). There were 238 patients in the PT group, 145 in the NT group, and 149 in the YT group.

The researchers found that additional full views and ultrasound were performed significantly less frequently in the YT group than in both the PT and NT groups. They also found that the PPV was increased for the YT group compared to both the PT and NT groups.


'/>"/>

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
American Roentgen Ray Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Breastfeeding promotes the growth of beneficial bacteria in the gut
2. IMPAKT Breast Cancer Conference: Oral presentation abstracts online
3. International molecular screening program for metastatic breast cancer AURORA at IMPAKT
4. Better sleep predicts longer survival time for women with advanced breast cancer
5. Lymph node ultrasounds more accurate in obese breast cancer patients
6. Surgeons and health care settings influence type of breast cancer surgery women undergo
7. Unemployment common after breast cancer treatment
8. Receiving chemotherapy after a breast cancer diagnosis may affect a patients employment
9. Breast cancer replicates brain development process
10. Gold nanoparticles help target, quantify breast cancer segments in a living cell
11. Benaroya Research Institute evaluates immunology approach to blocking breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: